Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RISPERDAL CONSTA vs RITLECITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RISPERDAL CONSTA vs RITLECITINIB: Safety Overview

Metric RISPERDAL CONSTA RITLECITINIB
Total FAERS Reports 140 1,441
Deaths Reported 29 1
Death Rate 20.7% 0.1%
Hospitalizations 56 47
Average Patient Age 45.0 yrs 34.7 yrs
% Female Patients N/A 65.0%
FDA Approval Date N/A Jun 23, 2023
Manufacturer N/A U.S. Pharmaceuticals
Route N/A ORAL
Marketing Status N/A Prescription